Apotea's net turnover for the second quarter of 2026 increased by 10.9 percent to just over SEK 2 billion, compared to SEK 1.83 billion during the corresponding period of the previous year. Organic growth was thus in line with the total increase, also landing at 10.9 percent.
Operating profit (EBIT) amounted to SEK 104.4 million (93.1). Adjusted for share-related compensation, operating profit landed at SEK 104.7 million (99.3), corresponding to an adjusted operating margin of 5.2 percent (5.4).
According to the company, operating profit was affected by higher depreciation related to the new logistics center in Varberg, but this was offset by improved cost efficiency in personnel and other external operating expenses.
We delivered good profitability and stable growth in the second quarter. At the same time, work continued with full force to accelerate our growth, comments Pär Svärdson, CEO of Apotea.
During the quarter, the company initiated new investments. At the end of April, the online pharmacy launched its website for the Norwegian market, apotea.no, with a focus on a beauty and health assortment. At the same time, the company's own brands are showing stable development.
During the quarter, we took the next step in Norway by scaling up sales of our beauty and health offerings via apotea.no. We also saw strong development for our own brands - which now have annual sales of over SEK 100 million, continues Pär Svärdson.
Sales of prescription drugs increased by 11.8 percent and now account for 38.1 percent of the company's total turnover. Cash flow from operating activities decreased during the quarter to SEK 76.8 million (165.3). This development is explained by increased inventory for the new center in Varberg and higher paid income tax.